Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DETERMINE: Capmatinib in MET-dysregulated Rare Cancers
NCT06988475Phase 3Recruiting
- Sponsor
- Cancer Research UK
- Start
- Nov 2024
- Primary completion
- Oct 2029
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of capmatinib in solid tumor and hematological malignancy, sponsored by Cancer Research UK. Primary endpoints: Objective Response at 24 weeks and Durable Clinical Benefit at 24 weeks. Started Nov 2024; status: recruiting.
02
Drugs
capmatinib
03
Conditions
solid tumorhematological malignancy
Beyond the preview
Go deeper on NCT06988475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06988475.